Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Sep 30, 2022 10:12pm
178 Views
Post# 34998937

RE:RE:Prothena and Management's Reporting

RE:RE:Prothena and Management's Reporting
Agree, Sniper007, except that Bioasis does not mention any partners or licensees on its website, at all. The only references are contained in other media such as videos, presentations and in filings.
 
This allows Bioasis to avoid being specific about anything.
 
There needs to be a push to get Bioasis to 'fess up about all of its dealings. There is a possibility that Bioasis has no agreements whatsoever under which work is being conducted. I'm not saying this is so but I am saying that Bioasis's obfuscations suggest the possibility that Bioasis is dead in the water.
 
It's time for Bioasis to come clean.
 
This is not an attack on Bioasis. The share price tells us that investors consider Bioasis to be worth 15¢. Bioasis needs to tell shareholders and investors whether it's worth 15¢ or whether it's worth more or less than that.
 
In my opinion, Bioasis is getting dangerously close to being a company that regulators might want to investigate.
 
jd
<< Previous
Bullboard Posts
Next >>